CD8A and neoplasm: Our experimental and clinical data highlight the value of an elevated ratio of tumor-reactive CD8+ T cells to immunosuppressive Treg cells in the BM as a predictor of immunotherapy responses, particularly to PD-1/PD-L1 inhibitors.